Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451(7181):914–918. https://doi.org/10.1038/nature06797

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koupenova M, Kehrel BE, Corkrey HA, Freedman JE (2017) Thrombosis and platelets: an update. Eur Heart J 38(11):785–791. https://doi.org/10.1093/eurheartj/ehw550

Article  CAS  PubMed  Google Scholar 

Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. ArteriosclerThrombVasc Biol. 2014 Nov;34(11):2363–71.https://doi.org/10.1161/ATVBAHA.114.304488. PMID: 25304324.

Foley JH, Conway EM (2016) Cross Talk Pathways Between Coagulation and Inflammation. Circ Res 118(9):1392–1408. https://doi.org/10.1161/CIRCRESAHA.116.306853

Article  CAS  PubMed  Google Scholar 

Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, Ashraf MZ (2017) Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc Natl Acad Sci USA 114(18):4763–4768. https://doi.org/10.1073/pnas.1620458114

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray Chaudhuri A, Nussenzweig A (2017) The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 18(10):610–621. https://doi.org/10.1038/nrm.2017.53

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alemasova EE, Lavrik OI (2019) Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res 47(8):3811–3827. https://doi.org/10.1093/nar/gkz120

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pascal JM, Ellenberger T (2015) The rise and fall of poly(ADP-ribose): An enzymatic perspective. DNA Repair (Amst). 32:10–16. https://doi.org/10.1016/j.dnarep.2015.04.008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lord CJ, Ashworth A (2017) PARP inhibitors: Synthetic lethality in the clinic. Science. 355(6330):1152–1158. https://doi.org/10.1126/science.aam7344

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72(21):5588–5599. https://doi.org/10.1158/0008-5472.CAN-12-2753

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol. 175(2):192–222. https://doi.org/10.1111/bph.13748

Article  CAS  PubMed  Google Scholar 

Huang D, Kraus WL (2022) The expanding universe of PARP1-mediated molecular and therapeutic mechanisms. Mol Cell. 82(12):2315–2334. https://doi.org/10.1016/j.molcel.2022.02.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alves-Lopes R, Touyz RM (2018) PARP-1 (Poly[ADP-Ribose] Polymerase-1). Hypertension 72(5):1087–1089. https://doi.org/10.1161/HYPERTENSIONAHA.118.11830

Article  CAS  PubMed  Google Scholar 

Veres B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, Szekeres G, Szabo C, Sumegi B (2003) Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. BiochemPharmacol 65(8):1373–1382. https://doi.org/10.1016/s0006-2952(03)00077-7

Article  CAS  Google Scholar 

Crocker IP, Kenny LC, Thornton WA, Szabo C, Baker PN (2005) Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia. Br J Pharmacol 144(6):772–780. https://doi.org/10.1038/sj.bjp.0706055

Article  CAS  PubMed  Google Scholar 

Chesebro JH, Rauch U, Fuster V, Badimon JJ (1997) Pathogenesis of thrombosis in coronary artery disease. Haemostasis 27(Suppl 1):12–18. https://doi.org/10.1159/000217477

Article  CAS  PubMed  Google Scholar 

Wang XB, Cui NH, Zhang S, Guo SR, Liu ZJ, Ming L (2017) PARP-1 Variant Rs1136410 Confers Protection against Coronary Artery Disease in a Chinese Han Population: A Two-Stage Case-Control Study Involving 5643 Subjects. Front Physiol 14(8):916. https://doi.org/10.3389/fphys.2017.00916

Article  Google Scholar 

Badimon L, Vilahur G (2014) Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 276(6):618–632. https://doi.org/10.1111/joim.12296

Article  CAS  PubMed  Google Scholar 

Henning RJ, Bourgeois M, Harbison RD (2018) Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. CardiovascToxicol 18(6):493–506. https://doi.org/10.1007/s12012-018-9462-2

Article  CAS  Google Scholar 

Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R, Pastore M, Fineschi D, Nami R (2000) Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 75(2–3):227–232. https://doi.org/10.1016/s0167-5273(00)00336-3

Article  CAS  PubMed  Google Scholar 

Zhang D, Hu X, Li J, Liu J, Baks-TeBulte L, Wiersma M, Malik NU, van Marion DMS, Tolouee M, Hoogstra-Berends F, Lanters EAH, van Roon AM, de Vries AAF, Pijnappels DA, de Groot NMS, Henning RH, Brundel BJJM (2019) DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD+ depletion in experimental atrial fibrillation. Nat Commun 10(1):1307. https://doi.org/10.1038/s41467-019-09014-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stoll G, Kleinschnitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112(9):3555–3562. https://doi.org/10.1182/blood-2008-04-144758

Article  CAS  PubMed  Google Scholar 

Chen J, Li X, Xu S, Zhang M, Wu Z, Zhang X, Xu Y, Chen Y (2020) Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities. Front Cell Neurosci 3(14):77. https://doi.org/10.3389/fncel.2020.00077

Article  CAS  Google Scholar 

Lip GY (2000) Hypertension and the prothrombotic state. J Hum Hypertens. 14(10–11):687–90. https://doi.org/10.1038/sj.jhh.1001051

Article  CAS  PubMed  Google Scholar 

Dluzen DF, Kim Y, Bastian P, Zhang Y, Lehrmann E, Becker KG, NorenHooten N, Evans MK (2017) MicroRNAs Modulate Oxidative Stress in Hypertension through PARP-1 Regulation. Oxid Med Cell Longev. 2017:3984280. https://doi.org/10.1155/2017/3984280

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dean SM, Abraham W (2010) Venous thromboembolic disease in congestive heart failure. Congest Heart Fail. 16(4):164–9. https://doi.org/10.1111/j.1751-7133.2010.00148.x

Article  PubMed  Google Scholar 

Cameron SJ, Russell HM, Owens AP 3rd (2018) Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental? Blood. 132(25):2619–2628. https://doi.org/10.1182/blood-2017-08-743237

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Hao H, Leeper NJ, Zhu L (2018) Early Career Committee. Thrombotic Regulation From the Endothelial Cell Perspectives. ArteriosclerThrombVasc Biol 38(6):e90–e95. https://doi.org/10.1161/ATVBAHA.118.310367

Article  CAS  Google Scholar 

Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F (2018) Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. VasculPharmacol 100:1–19. https://doi.org/10.1016/j.vph.2017.05.005

Article  CAS  Google Scholar 

Szabó C, Cuzzocrea S, Zingarelli B, O’Connor M, Salzman AL (1997) Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 100(3):723–35. https://doi.org/10.1172/JCI119585

Article  PubMed  PubMed Central  Google Scholar 

Gebhard C, Stähli BE, Shi Y, Camici GG, Akhmedov A, Hoegger L, Lohmann C, Matter CM, Hassa PO, Hottiger MO, Malinski T, Lüscher TF, Tanner FC (2011) Poly(ADP-ribose) polymerase-1 protects from oxidative stress induced endothelial dysfunction. BiochemBiophys Res Commun 414(4):641–646. https://doi.org/10.1016/j.bbrc.2011.09.029

Article  CAS  Google Scholar 

Wang Q, Zhao T, Zhang W, Yu W, Liu B, Wang Z, Qiao W, Lu Q, Wang A, Zhang M (2018) Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction. Front Pharmacol 9:882. https://doi.org/10.3389/fphar.2018.00882

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhananjayan R, Koundinya KS, Malati T, Kutala VK (2016) Endothelial Dysfunction in Type 2 Diabetes Mellitus. Indian J ClinBiochem. 31(4):372–9. https://doi.org/10.1007/s12291-015-0516-y